Sugi Predict
/ Targets
/ STK35
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to STK35 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus |
PHASE3 | UNKNOWN |
| Signal TrAnsduction Pathway Activity Analysis in OVarian cancER |
PHASE2/PHASE3 | RECRUITING |
| Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy |
PHASE2 | COMPLETED |
| Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) |
PHASE2 | COMPLETED |
| Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients |
PHASE2 | COMPLETED |
| Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma |
PHASE2 | UNKNOWN |
| A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... |
PHASE2 | COMPLETED |
| Everolimus for Children With Recurrent or Progressive Ependymoma |
PHASE2 | COMPLETED |
| Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer |
PHASE2 | COMPLETED |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma |
PHASE2 | COMPLETED |
| Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors |
PHASE2 | RECRUITING |
| Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor |
PHASE2 | ACTIVE_NOT_RECRUITING |
| FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers |
PHASE1 | RECRUITING |
| Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors |
PHASE1 | RECRUITING |
| First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors |
PHASE1 | COMPLETED |
| A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). |
PHASE1 | ACTIVE_NOT_RECRUITING |
| A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors |
PHASE1 | UNKNOWN |
| Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma |
PHASE1 | COMPLETED |
| Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713 |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| New Genes in the Carcinogenesis of Colorectal Cancer |
nan | UNKNOWN |
| Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children |
nan | COMPLETED |
| Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus |
nan | COMPLETED |
| SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases |
nan | NOT_YET_RECRUITING |
| LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers |
nan | COMPLETED |
| Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation |
nan | COMPLETED |
| Protein Intake and Step Reduction in Older Adults |
nan | COMPLETED |
| Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA |
nan | RECRUITING |
| Identification of Novel Targetable Kinases in SR-a GvHD |
nan | COMPLETED |
| Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies. |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a STK35 binder may also engage these)